Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Goodyear Tire & Rubber Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Goodyear Tire & Rubber Co trades at $6.54 (market cap $2.02B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.2× Goodyear Tire & Rubber Co's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| ACAD | GT | |
|---|---|---|
Market Cap | $4.49B | $2.02B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $11.55 |
52-Week Low | $20.06 | $5.58 |
Enterprise Value | $3.69B | $9.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Goodyear Tire & Rubber (GT) trades at $7.02, up 6.53% today, with a bullish technical signal from moving averages and oscillators. The stock shows deep value metrics with P/E of 4.69 and P/B of 0.66, but faces profitability challenges with negative net income margin of -11.64% and ROE of -52.56%. Recent developments include the company's move to the S&P SmallCap 600 and new NASA lunar tire contract, while Q1 2026 earnings beat estimates despite a net loss.
The outlook remains mixed with analyst consensus at Buy (34.62%) and price target of $8.80 offering 25% upside, but persistent operational headwinds and declining revenue trends pose significant risks. Investment opportunity lies in valuation discount and Goodyear Forward program benefits, though weak tire volumes and negative cash flow projections for 2026 require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
